natgillin/translations-raw huggingface dataset:
If the 60-minute infusion is well tolerated, all subsequent infusions may be administered over 30 minutes. 
Ako bolesnik dobro podnese 60-minutnu infuziju, sve iduće infuzije mogu se primijeniti tijekom 30 minuta.
In Study BO25041, bevacizumab exposure was similar compared to a typical adult at the same dose. 
U ispitivanju BO25041, izloženost bevacizumabu bila je slična onoj u tipičnog odraslog bolesnika pri istoj dozi.
Investigator assessment* 
Procjena ispitivača*
● Avastin can increase the risk of developing a weak heart. 
Avastin može povećati rizik od slabljenja srca.
The results for all secondary endpoints (investigator assessed EFS, and ORR and OS) were consistent in showing no improvement associated with the addition of bevacizumab to the RT/T arm compared with the RT/T arm alone. 
Rezultati za sve sekundarne mjere ishoda (preživljenje bez događaja prema ocjeni ispitivača te ORR i OS) bili su dosljedni u smislu da nisu pokazivali poboljšanje povezano s dodavanjem bevacizumaba kombinaciji RT/T u odnosu na skupinu koja je primala samo RT/T.
Patients with central nervous system metastases, including previously treated or resected brain lesions, were excluded. 
U ispitivanje nisu bili uključeni bolesnici s metastazama u središnjem živčanom sustavu, uključujući prethodno liječene ili odstranjene lezije mozga.
Trial results show that 94% (277 / 296) of eligible patients went on to receive single agent bevacizumab at cycle 7. 
Rezultati ispitivanja pokazuju da je 94% (277/296) bolesnika koji su ispunjavali uvjete u 7. ciklusu nastavilo liječenje samo bevacizumabom.
● if you have problems with wound healing following surgery, 
● u slučaju problema sa zacjeljivanjem rana nakon operacije,
Of the 722 patients in the trial, the majority of patients had HER2-negative disease (90%), with a small number of patients with unknown (8%) or confirmed HER2-positive status (2%), who had previously been treated with or were considered unsuitable for trastuzumab therapy. 
negativan oblik bolesti (90%), uz mali broj bolesnika u kojih status nije bio poznat (8%) ili su imali potvrđen HER2-pozitivan status (2%), te su prethodno ili bili liječeni trastuzumabom ili nisu bili smatrani pogodnima za liječenje trastuzumabom.
The clinical benefit, as measured by overall survival, was seen in all pre-specified patient subgroups, including those defined by age, sex, performance status, location of primary tumour, number of organs involved and duration of metastatic disease. 
Kliničko poboljšanje, mjereno ukupnim preživljenjem, uočeno je u svim unaprijed definiranim podskupinama bolesnika, uključujući i one određene dobi, spolom, funkcionalnim statusom, sijelom primarnog tumora, brojem zahvaćenih organa i trajanjem metastatske bolesti.
The efficacy data from trials AVF0780g and AVF2192g investigating Avastin in combination with 5-FU/FA-chemotherapy are summarised in Table 5. 
Podaci o djelotvornosti iz ispitivanja AVF0780g i AVF2192g, u kojima je ispitivana primjena lijeka Avastin u kombinaciji s kemoterapijom 5-FU/FA, sažeti su u Tablici 5.
For further information please refer to Table 3 'Adverse reactions reported in post-marketing setting.' 
Za dodatne informacije vidjeti Tablicu 3 „Nuspojave prijavljene nakon stavljanja lijeka u promet“.
a Hazard ratio was estimated from Cox proportional hazards models stratified by the duration of platinum free-interval prior to enrolling onto this study per eCRF (electronic case report form) and secondary surgical debulking status Yes/No 
a Omjer hazarda procjenjivao se Coxovim modelima proporcionalnog hazarda stratificiranima prema duljini razdoblja bez primjene platine prije uključivanja u ovo ispitivanje sukladno navodima u elektroničkim test listama ispitanika (engl. electronic case report form, eCRF) i statusu sekundarnog smanjenja tumorske mase kirurškim putem: Da/Ne
In addition, an independent review of the primary endpoint was also conducted. 
Dodatno je provedena i neovisna revizija primarne mjere ishoda.
Stopping your treatment with Avastin may stop the effect on tumour growth. 
Prekidom liječenja lijekom Avastin može prestati njegov učinak na rast tumora.
The findings ranged from asymptomatic declines in left ventricular ejection fraction to symptomatic CHF, requiring treatment or hospitalisation. 
Nalazi su se kretali od asimptomatskog smanjenja ejekcijske frakcije lijeve klijetke do simptomatskog kongestivnog zatajenja srca koje je zahtijevalo liječenje ili hospitalizaciju.
Avastin has not been shown to reduce your ability to drive or to use any tools or machines. 
Nije se pokazalo da Avastin smanjuje sposobnost upravljanja vozilima i rukovanja alatima i strojevima.
• Study E2100 (paclitaxel) 
• Ispitivanje E2100 (paklitaksel)
Avastin 10 mg/kg was given every 2 weeks until disease progression. 
Avastin u dozi od 10 mg/kg primjenjivao se svaka 2 tjedna do progresije bolesti.
All of these findings were reversible upon discontinuation of bevacizumab and sunitinib malate (see Hypertension, Proteinuria, PRES in section 4.4). 
Sve su nuspojave bile reverzibilne po prestanku liječenja bevacizumabom i sunitinib malatom (vidjeti Hipertenzija, Proteinurija i Sindrom reverzibilne posteriorne leukoencefalopatije u dijelu 4.4).
Marketing Authorisation Holder Roche Registration GmbH Emil-Barell-Strasse 1 
Roche Registration GmbH Emil-Barell-Strasse 1
It is not known whether bevacizumab is excreted in human milk. 
Nije poznato izlučuje li se bevacizumab u majčino mlijeko.
Table 18 Efficacy results from study BO17707 (ICON7) 
Tablica 18 Rezultati djelotvornosti za ispitivanje BO17707 (ICON7):
In this trial, there were two primary objectives: to show that XELOX was non-inferior to FOLFOX-4 and to show that Avastin in combination with FOLFOX-4 or XELOX chemotherapy was superior to chemotherapy alone. 
Ovo je ispitivanje imalo dva primarna cilja: pokazati neinferiornost protokola XELOX u odnosu na protokol FOLFOX-4 te pokazati da je liječenje lijekom Avastin u kombinaciji s kemoterapijskim protokolima FOLFOX-4 ili XELOX superiornije od liječenja samo kemoterapijom.
Objective Response Rate 1 
Stopa objektivnog odgovora 1
However, somnolence and syncope have been reported with Avastin use (see table 1 in section 4.8). 
Međutim, pri primjeni lijeka Avastin prijavljene su somnolencija i sinkopa (vidjeti tablicu 1 u dijelu 4.8).
• problems with wound healing after surgery, 
● problemi sa zacjeljivanjem rana nakon operacije,
Major or massive pulmonary haemorrhage/haemoptysis has been observed primarily in trials in patients with non-small cell lung cancer (NSCLC). 
Jako ili masivno plućno krvarenje/hemoptiza opaženo je ponajprije u ispitivanjima provedenima u bolesnika s karcinomom pluća nemalih stanica (NSCLC-om).
Results are presented in Table 23. 
Rezultati su prikazani u Tablici 23.
In study JO25567, all grade hypertension was observed in 77.3% of the patients who received Avastin in combination with erlotinib as first-line treatment for non-squamous NSCLC with EGFR activating mutations, compared to 14.3% of patients treated with erlotinib alone. 
U ispitivanju JO25567, hipertenzija svih stupnjeva primijećena je u 77,3% bolesnika koji su primali Avastin u kombinaciji s erlotinibom kao prvu liniju liječenja neskvamoznog NSCLC-a s aktivirajućim mutacijama EGFR-a u usporedbi s 14,3% bolesnika liječenih samo erlotinibom.
• The other ingredients are trehalose dihydrate, sodium phosphate, polysorbate 20 and water for injections. 
● Drugi sastojci su trehaloza dihidrat, natrijev fosfat, polisorbat 20 i voda za injekcije.
• fistula: abnormal tube-like connection between internal organs and skin or other tissues that are not normally connected, including connections between vagina and the gut in patients with cervical cancer. 
● fistula: neuobičajen spoj u obliku cjevčice između unutarnjih organa i kože ili drugih tkiva koja inače nisu povezana, uključujući spojeve između rodnice i probavnog sustava u bolesnica s rakom vrata maternice.
Administration of bevacizumab or its parental murine antibody to xenotransplant models of cancer in nude mice resulted in extensive anti-tumour activity in human cancers, including colon, breast, pancreas and prostate. 
Primjena bevacizumaba ili njegova parentalnog mišjeg protutijela na ksenotransplantacijske modele raka u golih miševa rezultirala je ekstenzivnom antitumorskom aktivnošću u ljudskim zloćudnim tumorima, uključujući rak kolona, dojke, gušterače i prostate.
A doctor or nurse will give you this diluted Avastin solution by intravenous infusion (a drip into your vein). 
Liječnik ili medicinska sestra će Vam tu razrijeđenu otopinu lijeka Avastin dati infuzijom u venu
Adjustment for these baseline factors resulted in a treatment hazard ratio of 0.78 (95% CI [0.63; 0.96], p=0.0219), indicating a 22% reduction in the risk of death for patients in the Avastin + IFN alfa-2a arm compared to IFN alfa-2a arm. 
Nakon prilagodbe za navedene ishodišne čimbenike dobiven je omjer rizika liječenja od 0,78 (95% CI [0,63;0,96]; p = 0,0219), koji ukazuje da je rizik od smrti u skupini Avastin + IFN alfa-2a bio 22% manji nego u bolesnika koji su primali IFN alfa-2a.
Therefore fertility preservation strategies should be discussed with women of child-bearing potential prior to starting treatment with Avastin. 
Stoga kod žena reproduktivne dobi treba razmotriti strategije za očuvanje plodnosti prije početka liječenja lijekom Avastin.
fluoropyrimidine/irinotecan or fluoropyrimidine/oxaliplatin based chemotherapy fluoropyrimidine/irinotecan or fluoropyrimidine/oxaliplatin based chemotherapy + Avastina 
kemoterapija na bazi fluoropirimidina/irinotekana ili fluoropirimidina/oksaliplatina kemoterapija na bazi fluoropirimidina/irinotekana ili fluoropirimidina/oksaliplatina + Avastin a
XELOX or XELOX + Avastin 
XELOX ili XELOX+ Avastin oksaliplatin
(p-value 
(p-vrijednost
• reduction in the number of white cells in the blood, and cells that help the blood clot, 
● smanjenje broja bijelih krvnih stanica i stanica koje pomažu u zgrušavanju krvi,
The most frequently observed adverse reactions across clinical trials in patients receiving Avastin were hypertension, fatigue or asthenia, diarrhoea and abdominal pain. 
Najčešće zabilježene nuspojave u svim kliničkim ispitivanjima u bolesnika koji su primali Avastin bile su hipertenzija, umor ili astenija, proljev i bol u abdomenu.
Table 6 Treatment regimens in trial NO16966 (mCRC) Treatment 
Tablica 6 Protokoli liječenja u ispitivanju NO16966 (metastatski karcinom kolona ili re ktuma)
Each ml of concentrate contains 25 mg of bevacizumab*. 
Jedan ml koncentrata sadrži 25 mg bevacizumaba*.
No significant difference was observed in the duration of overall survival between patients who received Avastin monotherapy compared to patients treated with FOLFOX-4. 
Nije opažena značajna razlika u duljini ukupnog preživljenja između bolesnika koji su primali Avastin u monoterapiji i bolesnika liječenih protokolom FOLFOX-4.
Bevacizumab binds selectively to a protein called human vascular endothelial growth factor (VEGF), which is found on the lining of blood and lymph vessels in the body. 
Bevacizumab se selektivno veže na protein koji se zove humani krvožilni endotelni čimbenik rasta (engl. vascular endothelial growth factor, VEGF), a nalazi se na ovojnici krvnih i limfnih žila u tijelu.
The primary endpoint was duration of survival. 
Primarna mjera ishoda bilo je trajanje preživljenja.
Severe side effects, which may be very common (affects more than 1 user in 10), include: 
Teške nuspojave koje mogu biti vrlo česte (javljaju se u više od 1 na 10 korisnika) uključuju:
In terms of safety, there was a higher overall incidence of Grade 3-5 AEs in study E3200 relative to study ML18147. 
Što se tiče sigurnosti primjene, u ispitivanju E3200 ukupna incidencija nuspojava stupnja 3-5 bila je veća nego u ispitivanju ML18147.
Severe side effects of unknown frequency (frequency cannot be estimated from the available data), include: 
Teške nuspojave nepoznate učestalosti (učestalost se ne može procijeniti iz dostupnih podataka)
The side effects listed below were seen when Avastin was given together with chemotherapy. 
Niže navedene nuspojave uočene su kada se Avastin primjenjivao zajedno s kemoterapijom.
Treatment of platinum-resistant recurrent disease: Avastin is administered in combination with one of the following agents - paclitaxel, topotecan (given weekly) or pegylated liposomal doxorubicin. 
Liječenje rekurentne bolesti rezistentne na platinu: Avastin se primjenjuje u kombinaciji s jednim od sljedećih lijekova - paklitakselom, topotekanom (primijenjenim jednom tjedno) ili pegiliranim liposomalnim doksorubicinom.
In addition, in study AVF3694g the incidences of all Grade CHF were similar between the anthracycline + Avastin (6.2%) and the anthracycline + placebo arms (6.0%). 
Nadalje, u ispitivanju AVF3694g incidencija kongestivnog zatajenja srca bilo kojeg stupnja bila je podjednaka u skupini koja je primala antraciklin + Avastin (6,2%) i skupini koja je primala antraciklin + placebo (6,0%).
Toxicity and adverse reactions included arterial hypertension and fatigue as well as CNS ischaemia with acute neurological deficit. 
Toksičnost i nuspojave su uključivali arterijsku hipertenziju i umor te ishemiju centralnog živčanog sustava s akutnim neurološkim deficitom.
• epidemiological studies\non-interventional or observational studies, 
iz epidemioloških ispitivanja odnosno neintervencijskih ili opservacijskih ispitivanja ili ocjenom izvješća o pojedinačnim slučajevima.
Neutropenia and infections (see section 4.8) 
Neutropenija i infekcije (vidjeti dio 4.8)
The primary endpoint was PFS based on investigator's assessment of disease progression based on radiological scans or CA 125 levels, or symptomatic deterioration per protocol. 
Primarna mjera ishoda bilo je preživljenje bez progresije bolesti, prema ispitivačevoj procjeni progresije bolesti na temelju radioloških snimaka, razine CA-125 ili simptomatskog pogoršanja po protokolu.
The European Medicines Agency has waived the obligation to submit the results of studies, in all subsets of the paediatric population, in breast carcinoma, adenocarcinoma of the colon and rectum, lung carcinoma (small cell and non-small cell carcinoma), kidney and renal pelvis carcinoma (excluding nephroblastoma, nephroblastomatosis, clear cell sarcoma, mesoblastic nephroma, renal medullary carcinoma and rhabdoid tumour of the kidney), ovarian carcinoma (excluding rhabdomyosarcoma and germ cell tumours), fallopian tube carcinoma (excluding rhabdomyosarcoma and germ cell tumours), peritoneal carcinoma (excluding blastomas and sarcomas) and cervix and corpus uteri carcinoma. 
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Avastin u svim podskupinama pedijatrijske populacije u indikacijama karcinoma dojke, adenokarcinoma kolona i rektuma, karcinoma pluća (malih i nemalih stanica), karcinoma bubrega i bubrežne zdjelice (izuzev nefroblastoma, nefroblastomatoze, svjetlostaničnog sarkoma, mezoblastičnog nefroma, medularnog karcinoma bubrega i rabdoidnog tumora bubrega), karcinoma jajnika (izuzev rabdomiosarkoma i tumora germinativnih stanica), karcinoma jajovoda (izuzev rabdomiosarkoma i tumora germinativnih stanica), peritonealnog karcinoma (izuzev blastoma i sarkoma) te karcinoma vrata i tijela uterusa.
These results suggest that close clinical observation with appropriate cardiac assessments should be considered for patients exposed to cumulative doxorubicin doses greater than 300 mg/m2 when combined with bevacizumab. 
Ovi rezultati upućuju na potrebu pomnog kliničkog nadzora uz odgovarajuću procjenu srčane funkcije u bolesnika izloženih kumulativnim dozama doksorubicina višima od 300 mg/m u kombinaciji s bevacizumabom.
Patients should be monitored for signs and symptoms of CNS bleeding, and Avastin treatment discontinued in cases of intracranial bleeding. 
Bolesnike treba nadzirati kako bi se uočili eventualni znakovi i simptomi krvarenja u SŽS-u te u slučaju intrakranijalnog krvarenja obustaviti liječenje lijekom
• muscle and joint pain, muscular weakness, 
● bol u mišićima i zglobovima, slabost mišića,
Individual cases and clusters of serious ocular adverse reactions have been reported following unapproved intravitreal use of Avastin compounded from vials approved for intravenous administration in cancer patients. 
Prijavljeni su pojedinačni slučajevi i skupine ozbiljnih očnih nuspojava nakon neodobrene intravitrealne primjene lijeka Avastin pripremljenog iz bočica odobrenih za intravensku primjenu u bolesnika s malignom bolešću.
There were neither statistically significant nor clinically relevant differences in bevacizumab clearance in patients receiving Avastin monotherapy compared to patients receiving Avastin in combination with interferon alfa-2a, erlotinib or chemotherapies (IFL, 5-FU/LV, carboplatin/paclitaxel, capecitabine, doxorubicin or cisplatin/gemcitabine). 
Nije bilo ni statistički ni klinički značajnih razlika u klirensu bevacizumaba između bolesnika koji su primali samo Avastin i bolesnika koji su primali Avastin u kombinaciji s interferonom alfa-2a, erlotinibom ili kemoterapeuticima (IFL, 5-FU/LV, karboplatin/paklitaksel, kapecitabin, doksorubicin ili cisplatin/gemcitabin).
• dry skin, flaking and inflammation of the skin, change in skin colour, 
● suhu kožu, perutanje i upalu kože, promjenu boje kože, ● gubitak tjelesne težine,
The frequency of GI-vaginal fistulae in the group treated with Avastin + chemotherapy was higher in patients with recurrence within the field of prior radiation (16.7%) compared with patients with no prior radiation and/ or no recurrence inside the field of prior radiation (3.6%). 
Učestalost gastrointestinalno-vaginalnih fistula u skupini liječenoj lijekom Avastin + kemoterapijom bila je viša u bolesnica s recidivom unutar područja koje je prethodno bilo zračeno (16,7%) nego u onih koje prethodno nisu primale zračenje i/ili onih bez recidiva unutar područja koje je prethodno bilo zračeno
Hypersensitivity reactions and infusion reactions (not known); with the following possible co-manifestations: dyspnoea/difficulty breathing, flushing/redness/rash, hypotension or hypertension, oxygen desaturation, chest pain, rigors and nausea/vomiting (see also section 4.4 and Hypersensitivity reactions/infusion reactions above) 
Reakcije preosjetljivosti i infuzijske reakcije (nepoznato), sa sljedećim mogućim pratećim znakovima: dispneja/otežano disanje, navale vrućine/crvenilo/osip, hipotenzija ili hipertenzija, smanjena saturacija kisikom, bol u prsištu, tresavica i mučnina/povraćanje (vidjeti i dio 4.4 i Reakcije preosjetljivosti/infuzijske reakcije u prethodnom tekstu)
Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. 
Bevacizumab se vezuje na krvožilni endotelni faktor rasta (engl. vascular endothelial growth factor, VEGF), ključni medijator vaskulogeneze i angiogeneze, i time inhibira vezivanje VEGF-a za receptore Flt1 (VEGFR-1) i KDR (VEGFR-2) na površini endotelnih stanica.
Analyses of the clinical safety data suggest that the occurrence of hypertension and proteinuria with Avastin therapy are likely to be dose-dependent. 
Analize kliničkih podataka o sigurnosti primjene upućuju na to da pojava hipertenzije i proteinurije tijekom liječenja lijekom Avastin vjerojatno ovisi o dozi.
In all clinical trials, bevacizumab was administered as an IV infusion. 
U svim je kliničkim ispitivanjima bevacizumab primijenjen u obliku intravenske infuzije.
If this happens you should talk to your doctor, pharmacist or nurse immediately. 
Ako se to dogodi, morate se odmah obratiti liječniku, ljekarniku ili medicinskoj sestri.
Table 2 also includes adverse reactions which are considered by the MAH to be clinically significant or severe. 
U Tablicu 2 su uključene i one nuspojave koje nositelj odobrenja smatra klinički značajnima ili teškima.
Table 13 Efficacy results for trial BO17704 
Tablica 13 Rezultati djelotvornosti za ispitivanje BO17704
Decreased neutrophil count, decreased white blood cell count and presence of urine protein may be associated with Avastin treatment. 
Smanjen broj neutrofila, smanjen broj leukocita i prisutnost proteina u mokraći mogu biti povezani s liječenjem lijekom Avastin.
Possible risk factors include squamous cell histology, treatment with antirheumatic/anti-inflammatory substances, treatment with anticoagulants, prior radiotherapy, Avastin therapy, previous medical history of atherosclerosis, central tumour location and cavitation of tumours prior to or during therapy. 
Mogući čimbenici rizika obuhvaćaju histološki tip tumora skvamoznih stanica, liječenje antireumatskim/protuupalnim lijekovima, liječenje antikoagulansima, prethodnu radioterapiju, terapiju lijekom Avastin, anamnezu ateroskleroze te središnju lokalizaciju i kavitacije tumora prije ili tijekom liječenja.
Prior anthracyclines exposure and/or prior radiation to the chest wall may be possible risk factors for the development of CHF. 
Prethodna izloženost antraciklinima i/ili zračenje stijenke prsnog koša mogući su čimbenici rizika za razvoj kongestivnog zatajenja srca.
Alternatively, a 1.25 mg/m2 dose could be administered over 30 minutes on Days 1-5 
Alternativno se mogla primjenjivati doza od 1,25 mg/m2 tijekom 30 minuta od 1. do 5. dana svaka 3 tjedna.
Recurrence of cancer within the field of prior radiation is an additional important risk factor for the development of GI-vaginal fistulae. 
Recidiv karcinoma unutar područja koje je prethodno bilo zračeno dodatan je važan čimbenik rizika za razvoj gastrointestinalno-vaginalne fistule.
Eye disorder, Lacrimation increased 
Poremećaji oka poremećaj oka, pojačano suzenje
This group of medical terms may involve the same underlying pathophysiology (e.g. arterial thromboembolic reactions include cerebrovascular accident, myocardial infarction, transient ischaemic attack and other arterial thromboembolic reactions). 
Ovaj skup medicinskih pojmova može imati istu patofiziološku podlogu (npr. arterijske tromboembolijske reakcije uključuju cerebrovaskularni incident, infarkt miokarda, tranzitorne ishemijske atake i druge arterijske tromboembolijske reakcije).
New cases of ovarian failure were reported in 2.6% patients in the mFOLFOX-6 group compared to 39% in the mFOLFOX-6 + bevacizumab group. 
bolesnica u skupini mFOLFOX-6 u usporedbi s 39% njih u skupini mFOLFOX-6 + bevacizumab.
Avastin may impair female fertility (see sections 4.6 and 4.8). 
Avastin može narušiti plodnost u žena (vidjeti dijelove 4.6 i 4.8).
In Avastin clinical trials, gastrointestinal fistulae (all grade) have been reported with an incidence of up to 2% in patients with metastatic colorectal cancer and ovarian cancer, but were also reported less commonly in patients with other types of cancer. 
U kliničkim ispitivanjima lijeka Avastin prijavljena incidencija gastrointestinalnih fistula (svih stupnjeva) iznosila je do 2% u bolesnika s metastatskim kolorektalnim karcinomom i karcinomom jajnika, no one su prijavljene manje često i u bolesnika s drugim oblicima karcinoma.
7.5 mg/kg IV 30-90 min 
7,5 mg/kg i.v. 30-90 min
The incidence of CNS bleeding in patients with untreated CNS metastases receiving bevacizumab has not been prospectively evaluated in randomised clinical trials. 
Incidencija krvarenja u SŽS-u u bolesnika s neliječenim metastazama u SŽS-u koji su primali bevacizumab nije prospektivno ocijenjena u randomiziranim kliničkim ispitivanjima.
Avastin is also used for the treatment of adult patients with advanced non-small cell lung cancer when cancer cells have specific mutations of a protein called epidermal growth factor receptor (EGFR). 
Avastin se koristi i za liječenje odraslih bolesnika s uznapredovalim rakom pluća nemalih stanica kada stanice raka imaju specifične mutacije proteina koji se zove receptor epidermalnog faktora rasta (engl. epidermal growth factor receptor, EGFR).
The 649 randomised patients (641 treated) had Karnofsky Performance Status (KPS) of ≥ 70%, 
Randomizirano je 649 bolesnika (od kojih je 641 liječen) funkcionalnog statusa po Karnofskom
878 patients were randomised to the two arms. 
U te je dvije skupine randomizirano 878 bolesnika.